During the last few years, tyrosine kinase receptor inhibitors such as nintedanib, developed and already used for the treatment of non-small cell lung carcinoma and other cancers, have been tested in phase II and III clinical trials for the treatment of IPF [48–52]. Here, NTRK1 is linked to idiopathic pulmonary fibrosis.